Top Page
Shandong Xinhua Pharmaceutical Company Limited Class H
(0719)
Shandong Xinhua Pharmaceutical Company Limited Class H (0719) vs. iShares MSCI Hong Kong ETF (EWH)
Shandong Xinhua Pharmaceutical Company Limited Class H Business Overview & Revenue Model
Shandong Xinhua Pharmaceutical Company Limited Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.69B | 8.47B | 8.10B | 7.50B | 6.56B | 6.01B |
| Gross Profit | 1.79B | 2.04B | 2.32B | 2.04B | 1.77B | 1.81B |
| EBITDA | 491.49M | 1.11B | 1.09B | 1.01B | 908.67M | 856.79M |
| Net Income | 385.17M | 470.02M | 496.51M | 411.06M | 348.55M | 324.86M |
Balance Sheet | ||||||
| Total Assets | 9.94B | 9.02B | 8.29B | 8.27B | 7.33B | 7.09B |
| Cash, Cash Equivalents and Short-Term Investments | 1.35B | 1.25B | 918.33M | 1.16B | 744.66M | 855.77M |
| Total Debt | 2.27B | 1.35B | 1.08B | 1.38B | 1.04B | 1.09B |
| Total Liabilities | 4.05B | 3.80B | 3.51B | 3.92B | 3.68B | 3.70B |
| Stockholders Equity | 5.63B | 4.99B | 4.55B | 4.13B | 3.47B | 3.22B |
Cash Flow | ||||||
| Free Cash Flow | 282.70M | 155.19M | ― | 513.48M | 9.89M | 140.00M |
| Operating Cash Flow | 339.26M | 367.61M | 265.28M | 758.24M | 259.12M | 420.19M |
| Investing Cash Flow | -104.75M | -212.21M | ― | ― | ― | ― |
| Financing Cash Flow | -206.30M | 184.78M | -196.11M | ― | ― | 35.04M |
Shandong Xinhua Pharmaceutical Company Limited Class H Technical Analysis
Shandong Xinhua Pharmaceutical Company Limited Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$9.00B | 13.67 | 9.12% | 4.93% | -29.18% | -51.49% | |
72 Outperform | HK$13.33B | 12.44 | 25.92% | 3.93% | 19.05% | 13.68% | |
58 Neutral | HK$10.24B | 11.58 | 7.48% | 4.47% | 1.65% | -16.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$12.32B | -138.95 | -1.87% | 0.87% | 19.21% | -115.91% | |
41 Neutral | HK$13.81B | -61.38 | -2.79% | ― | 29.21% | 80.37% |
Shandong Xinhua Pharmaceutical Company Limited Class H Corporate Events
Shandong Xinhua Pharmaceutical has updated and adopted revised terms of reference for its Board Audit Committee, effective 31 December 2025, to strengthen corporate governance and regulatory compliance. The revised framework clarifies that the Audit Committee, composed mainly of independent non-executive directors including at least one accounting professional, will exercise certain supervisory board powers under PRC Company Law, define stricter qualification and independence requirements for committee members, and set out clear responsibilities for the committee convener and mechanisms for filling vacancies, thereby reinforcing oversight of the company’s financial reporting and internal control for the benefit of investors and other stakeholders.
The most recent analyst rating on (HK:0719) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Shandong Xinhua Pharmaceutical Company Limited Class H stock, see the HK:0719 Stock Forecast page.
Shandong Xinhua Pharmaceutical has updated and adopted, as of 31 December 2025, the terms of reference for its Board-level Nomination Committee, first established in 2002, to align with PRC company law, governance codes for listed companies, and Hong Kong Listing Rules. The revised charter formalises the committee’s composition, requiring four to six directors with at least one of a different gender and at least half being independent non-executive directors, mandates that the committee chair be an independent director appointed by the board, and sets out their responsibilities, eligibility criteria, and tenure. It also creates a dedicated working group led by the deputy general manager for human resources to support the committee’s preparatory and information-gathering work on board and senior management candidates, reinforcing the company’s governance structure and succession planning framework for the benefit of shareholders and other stakeholders.
The most recent analyst rating on (HK:0719) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Shandong Xinhua Pharmaceutical Company Limited Class H stock, see the HK:0719 Stock Forecast page.
Shandong Xinhua Pharmaceutical has updated and re-adopted the terms of reference for its Board-level Remuneration and Appraisal Committee, originally approved in 2002 and most recently revised on 31 December 2025, to align with PRC corporate law, governance codes, independent director rules, its Articles of Association and Hong Kong Listing Rules. The revised document formalises the committee’s composition, independence requirements, leadership by an independent non-executive director, member qualifications, responsibilities and confidentiality obligations, and embeds the committee within the board’s administrative structure, reinforcing remuneration oversight and governance standards for directors and senior management to better safeguard shareholder interests.
The most recent analyst rating on (HK:0719) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Shandong Xinhua Pharmaceutical Company Limited Class H stock, see the HK:0719 Stock Forecast page.
Shandong Xinhua Pharmaceutical Company Limited announced that it has received a Drug Registration Certificate from China’s National Medical Products Administration for its domestically produced 80mg valsartan capsules, a prescription medicine used to treat mild to moderate primary hypertension. The approval confirms that the product meets national drug registration and quality standards and allows the company to proceed toward commercial production and sales once pharmaceutical production quality management requirements are fulfilled, potentially strengthening its cardiovascular portfolio and competitive position in China’s hypertension treatment market.
Shandong Xinhua Pharmaceutical Company Limited has obtained a Drug Registration Certificate from China’s National Medical Products Administration for its Phloroglucinol Injection, a prescription chemical drug used to treat acute spasmodic pain related to digestive and biliary tract dysfunctions, urethral, bladder and kidney colic, and gynecological spasmodic pain. The approval, following the submission and review of marketing application materials since July 2024, enables the company to move toward commercial production and sale of the injection once it meets pharmaceutical production quality management standards, potentially enhancing its product portfolio in the domestic pain-management and antispasmodic treatment segment.
Shandong Xinhua Pharmaceutical Company Limited has received a Drug Registration Certificate from China’s National Medical Products Administration for its Oseltamivir Phosphate for Suspension, an over-the-counter oral antiviral formulation. The approval, following a review process that began with a marketing application in March 2024, confirms the product meets regulatory standards for quality, labeling and production, and requires a pre‑market GMP compliance inspection, paving the way for future commercialisation and potentially strengthening the company’s position in the influenza treatment market.
Shandong Xinhua Pharmaceutical Company Limited announced that its Epinephrine Hydrochloride Injection has passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, as approved by the National Medical Products Administration. This approval marks a significant milestone for the company, enhancing its product credibility and potentially strengthening its market position in the pharmaceutical industry, particularly in the treatment of severe dyspnea, anaphylactic shock, and as a primary rescue drug for cardiopulmonary resuscitation.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the marketing application of its Prednisolone Acetate, a chemical active pharmaceutical ingredient. This product is primarily used for treating allergic and autoimmune inflammatory diseases, and its approval is expected to enhance the company’s market position and provide significant benefits to stakeholders by expanding its product offerings in the pharmaceutical market.
Shandong Xinhua Pharmaceutical Company Limited has announced that it has received the Drug Registration Certificate for its Lidocaine and Prilocaine Cream from the National Medical Products Administration. This approval marks a significant step for the company, as it allows the product to be marketed and sold, potentially enhancing its market position and offering new opportunities for growth in the pharmaceutical industry.
Shandong Xinhua Pharmaceutical Company Limited has announced the approval of its marketing application for Vonoprazan Fumarate, a chemical active pharmaceutical ingredient used to treat reflux esophagitis. This approval, granted by the National Medical Products Administration, positions the product within China’s public medical institutions, where related sales reached approximately RMB 825 million in 2024, indicating significant market potential and impact for the company.
Shandong Xinhua Pharmaceutical Company Limited has announced the receipt of the Drug Registration Certificate for its Alendronate Sodium Oral Solution, approved by the National Medical Products Administration. This approval allows the company to produce and sell the drug, enhancing its product portfolio and potentially strengthening its market position in the pharmaceutical industry.
Shandong Xinhua Pharmaceutical Company Limited held an Extraordinary General Meeting (EGM) where all proposed resolutions, including amendments to the articles of association and meeting procedures, were passed. The meeting saw participation from a significant number of shareholders, with a high percentage of votes in favor of the resolutions, indicating strong shareholder support for the company’s governance changes.
Shandong Xinhua Pharmaceutical Company Limited announced its unaudited consolidated results for the nine months ending September 30, 2025. The company reported a slight increase in operating income by 0.42% compared to the previous year, while net profit attributable to shareholders decreased by 25.53%. Despite the decline in net profit, the company experienced a 26.65% increase in net cash flow from operating activities, indicating improved operational efficiency.
Shandong Xinhua Pharmaceutical Company Limited has announced the renewal of its trademark license agreement with Shandong Xinhua Pharmaceutical Branch of Hualu Holdings Co. Ltd. This agreement, effective from January 1, 2026, to December 31, 2028, allows the company to continue using the ‘Xinhua’ trademark. This renewal is part of a continuing connected transaction and reflects the company’s strategic focus on maintaining its brand identity and market position. The transaction is subject to reporting and review requirements under Hong Kong’s Listing Rules but is exempt from certain approval requirements, indicating a streamlined regulatory process.
Shandong Xinhua Pharmaceutical Company Limited has announced that it has received the Drug Registration Certificate for its Bisoprolol Fumarate Tablets from the National Medical Products Administration. This approval marks a significant step for the company in expanding its product offerings in the prescription drug market, potentially enhancing its market position and stakeholder value.
Shandong Xinhua Pharmaceutical Company Limited has announced a board meeting scheduled for October 24, 2025, to review and approve the unaudited financial results for the nine months ending September 30, 2025. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential strategic directions.
Shandong Xinhua Pharmaceutical Company Limited has announced an extraordinary general meeting (EGM) to be held on October 24, 2025, in Zibo City, Shandong Province, China. The meeting aims to consider and approve proposed amendments to the company’s articles of association and the rules and procedures for general and board meetings. These changes are intended to streamline the company’s governance processes and enhance operational efficiency.